IPO hopeful rEVO puts off its plans for a $75M debut

Massachusetts biotech rEVO Biologics is postponing its efforts to go public in a $75 million IPO. The company, formerly called GTC Therapeutics, had planned to spend its haul on developing its lead drug, ATryn, to treat preeclampsia. More

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.